Kansas Bioscience Authority

Advanced Animal Diagnostics, Inc. focuses on the research, development, and commercialization of on-farm diagnostic tools aimed at the early detection of subclinical mastitis in dairy cows. Based in Durham, North Carolina, the company offers products such as the QScout Farm Lab, an analyzer system that identifies infections in dairy cows before symptoms manifest, and the QScout Milk Leukocyte Differential rapid test, which analyzes milk to detect and differentiate white blood cells indicative of mastitis. Additionally, Advanced Animal Diagnostics provides solutions like QuickSmear, a rapid differential slide that aids in animal research, and the SCC+ System for early mastitis detection. These diagnostic tools are designed to enhance animal health management, benefiting veterinarians and livestock producers by enabling timely detection of infections and supporting informed treatment decisions. Founded in 2001, the company aims to improve the overall health and productivity of production animals.

Flow Forward Medical is a company focused on developing vascular access solutions to enhance post-surgery success rates. Its primary product, the Arteriovenous Fistula Eligibility (AFE) System, is a small, temporary external blood pump engineered to promote flow-mediated dilation of veins. This innovation aims to increase the eligibility of patients for arteriovenous fistula (AVF) procedures, which are critical for hemodialysis patients. By improving the establishment of reliable AVFs, Flow Forward Medical seeks to reduce both morbidity and mortality among these patients, while also lowering overall healthcare costs. Founded in 2014 by Frank Nicholas Franano, the company is based in Olathe, Kansas.

Innara Health, Inc. specializes in developing neonatal care technologies aimed at improving the health and development outcomes for preterm and full-term infants, as well as children with developmental needs. The company is best known for its NTrainer System, a medical device that supports the development of non-nutritive sucking skills in newborns, which is crucial for feeding. This system assists caregivers in neonatal and pediatric intensive care units by providing insights into effective treatment strategies for infants facing feeding challenges. Founded in 2006 and based in Olathe, Kansas, Innara Health was previously known as KCBioMedix, Inc. until it rebranded in 2013. The company’s innovations are focused on enhancing the quality of life for infants and their families, as well as improving overall feeding outcomes in hospital settings.

Artio Medical, Inc. is a medical device company focused on developing and commercializing catheter-based solutions for cardiovascular diseases. Based in Olathe, Kansas, the company specializes in endovascular devices designed for embolization of vessels, aneurysms, and other vascular structures. Its product offerings include Solus Gold and Solus Flex, both embolization devices featuring unique delivery systems, as well as Aneura and Endura, which combine coils and accessory balloons for the immediate occlusion of saccular and cerebral aneurysms, respectively. Artio Medical was founded in 2011 and was previously known as Metactive Medical, Inc. before rebranding in February 2020. The company operates as a subsidiary of Novita Therapeutics, LLC, and its innovations aim to enhance the speed and safety of vascular occlusion procedures for physicians.

Advanced Animal Diagnostics, Inc. focuses on the research, development, and commercialization of on-farm diagnostic tools aimed at the early detection of subclinical mastitis in dairy cows. Based in Durham, North Carolina, the company offers products such as the QScout Farm Lab, an analyzer system that identifies infections in dairy cows before symptoms manifest, and the QScout Milk Leukocyte Differential rapid test, which analyzes milk to detect and differentiate white blood cells indicative of mastitis. Additionally, Advanced Animal Diagnostics provides solutions like QuickSmear, a rapid differential slide that aids in animal research, and the SCC+ System for early mastitis detection. These diagnostic tools are designed to enhance animal health management, benefiting veterinarians and livestock producers by enabling timely detection of infections and supporting informed treatment decisions. Founded in 2001, the company aims to improve the overall health and productivity of production animals.

Health Outcomes Sciences LLC specializes in providing information technology solutions aimed at enhancing the quality of healthcare delivery. Founded in 2005 and based in Overland Park, Kansas, the company focuses on translating advances in clinical research into practical decision-support products and services for healthcare providers and organizations. Its ePRISM platform allows for the creation and deployment of evidence-based predictive models as web-based tools, facilitating personalized educational materials and informed consent documents. This platform is designed to assist in various clinical applications, including clinical decision support, shared medical decision-making, and patient education. Additionally, Health Outcomes Sciences offers readmission models that estimate risks associated with conditions such as heart failure and pneumonia, thereby aiding in the reduction of hospital readmission rates. By leveraging predictive analytics, the company enables clinicians to better understand the relationships between clinical variables and patient outcomes, ultimately improving individualized patient care.

Flow Forward Medical is a company focused on developing vascular access solutions to enhance post-surgery success rates. Its primary product, the Arteriovenous Fistula Eligibility (AFE) System, is a small, temporary external blood pump engineered to promote flow-mediated dilation of veins. This innovation aims to increase the eligibility of patients for arteriovenous fistula (AVF) procedures, which are critical for hemodialysis patients. By improving the establishment of reliable AVFs, Flow Forward Medical seeks to reduce both morbidity and mortality among these patients, while also lowering overall healthcare costs. Founded in 2014 by Frank Nicholas Franano, the company is based in Olathe, Kansas.

Aratana Therapeutics, Inc. is a biopharmaceutical company dedicated to developing and commercializing therapeutics for dogs and cats in the United States. Founded in 2010 and headquartered in Leawood, Kansas, the company focuses on addressing unmet medical needs in companion animal care through high-quality medicines. Its product portfolio includes various therapeutics, such as NOCITA for post-operative pain management in dogs, ENTYCE for appetite stimulation, and GALLIPRANT for pain and inflammation associated with osteoarthritis. Aratana is also advancing treatments for conditions like osteosarcoma in dogs and a range of therapies for cats, including a specialized formulation for pain management and treatments for feline herpes virus-induced conditions. The company has established collaboration agreements with other health organizations to enhance the development and commercialization of its products.

Aratana Therapeutics, Inc. is a biopharmaceutical company dedicated to developing and commercializing therapeutics for dogs and cats in the United States. Founded in 2010 and headquartered in Leawood, Kansas, the company focuses on addressing unmet medical needs in companion animal care through high-quality medicines. Its product portfolio includes various therapeutics, such as NOCITA for post-operative pain management in dogs, ENTYCE for appetite stimulation, and GALLIPRANT for pain and inflammation associated with osteoarthritis. Aratana is also advancing treatments for conditions like osteosarcoma in dogs and a range of therapies for cats, including a specialized formulation for pain management and treatments for feline herpes virus-induced conditions. The company has established collaboration agreements with other health organizations to enhance the development and commercialization of its products.

Innara Health, Inc. specializes in developing neonatal care technologies aimed at improving the health and development outcomes for preterm and full-term infants, as well as children with developmental needs. The company is best known for its NTrainer System, a medical device that supports the development of non-nutritive sucking skills in newborns, which is crucial for feeding. This system assists caregivers in neonatal and pediatric intensive care units by providing insights into effective treatment strategies for infants facing feeding challenges. Founded in 2006 and based in Olathe, Kansas, Innara Health was previously known as KCBioMedix, Inc. until it rebranded in 2013. The company’s innovations are focused on enhancing the quality of life for infants and their families, as well as improving overall feeding outcomes in hospital settings.

Osteogenix is a therapeutic products company with novel products for the large and rapidly growing area of bone repair and bone growth. Osteogenix was founded in 2005 to clinically develop and commercialize the osteo-pharmacologic platform discovered and patented by Dr. Mundy and his associates. Osteogenix assembled an outstanding team of expert advisors, many of whom have been principal investigators in key orthobiologics trials.

IGXBio, Inc. is a biotechnology company focused on the development of advanced DNA immunotherapies specifically aimed at treating HIV infection. The company has created a proprietary DNA composition that synthetically mimics the virus, which helps to stimulate an immune response. This innovative approach aims to be less toxic than existing AIDS drug cocktails, potentially allowing healthcare providers to reduce the incidence of infections, particularly those related to HIV.

VasoGenix Pharmaceuticals, Inc., is developing intravenous (IV) and controlled release drug treatments for addressing Heart Failure ("HF") and other cardiac diseases in order to reduce the recurrence of these diseases and their resulting hospital and medical costs. VasoGenix is initially focusing on a major unmet critical need in Acute Decompensated Heart Failure ("ADHF"), when the symptoms of HF become severe enough to require hospitalization.